Barrington Research cut shares of Pharmerica Corporation (NYSE:PMC) from an outperform rating to an underperform rating in a research report released on Wednesday. Barrington Research also issued estimates for Pharmerica Corporation’s Q4 2018 earnings at $0.59 EPS.

Several other research analysts have also recently issued reports on PMC. Zacks Investment Research raised Pharmerica Corporation from a sell rating to a hold rating and set a $27.00 target price on the stock in a research report on Tuesday, May 16th. ValuEngine cut Pharmerica Corporation from a buy rating to a hold rating in a research report on Friday, June 2nd. BidaskClub cut Pharmerica Corporation from a hold rating to a sell rating in a research report on Monday, July 31st. KeyCorp cut Pharmerica Corporation to an overweight rating in a research report on Wednesday, August 2nd. Finally, UBS AG reaffirmed a neutral rating and set a $29.25 target price (up previously from $26.00) on shares of Pharmerica Corporation in a research report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $28.83.

Shares of Pharmerica Corporation (NYSE PMC) traded down 0.17% during trading on Wednesday, hitting $29.05. The company had a trading volume of 346,427 shares. The stock has a market capitalization of $904.07 million, a price-to-earnings ratio of 39.36 and a beta of 0.92. The stock has a 50-day moving average of $26.64 and a 200 day moving average of $24.94. Pharmerica Corporation has a 12-month low of $19.20 and a 12-month high of $29.10.

Pharmerica Corporation (NYSE:PMC) last announced its quarterly earnings data on Wednesday, August 2nd. The company reported $0.47 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.47. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 1.05%. The firm had revenue of $592 million during the quarter, compared to analysts’ expectations of $592.96 million. During the same quarter last year, the firm posted $0.47 earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. On average, analysts predict that Pharmerica Corporation will post $1.92 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/12/barrington-research-lowers-pharmerica-corporation-nysepmc-to-underperform.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank bought a new position in shares of Pharmerica Corporation during the fourth quarter valued at about $3,864,000. Teachers Advisors LLC boosted its position in shares of Pharmerica Corporation by 4.9% in the fourth quarter. Teachers Advisors LLC now owns 357,845 shares of the company’s stock valued at $9,000,000 after buying an additional 16,715 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Pharmerica Corporation by 0.8% in the first quarter. Louisiana State Employees Retirement System now owns 12,500 shares of the company’s stock valued at $293,000 after buying an additional 100 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its position in shares of Pharmerica Corporation by 9.1% in the first quarter. Candriam Luxembourg S.C.A. now owns 72,000 shares of the company’s stock valued at $1,685,000 after buying an additional 6,000 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in shares of Pharmerica Corporation by 32.6% in the first quarter. Fisher Asset Management LLC now owns 70,707 shares of the company’s stock valued at $1,655,000 after buying an additional 17,395 shares during the last quarter. 92.84% of the stock is currently owned by institutional investors.

About Pharmerica Corporation

Receive News & Stock Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related stocks with our FREE daily email newsletter.